Unknown PHASE3 INTERVENTIONAL 2-arm NCT00465491

Study of Picoplatin Efficacy After Relapse (SPEAR)

A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.

Sponsor: Poniard Pharmaceuticals

Conditions Small Cell Lung Cancer

Interventions best supportive care picoplatin

Updated 7 times since 2017 Last updated: Apr 13, 2009 Started: Apr 30, 2007 Primary completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00465491, this PHASE3 trial focuses on Small Cell Lung Cancer and remains ongoing. Sponsored by Poniard Pharmaceuticals, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poniard Pharmaceuticals

Data source: Poniard Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Asarwa, India , Baia Mare, Romania , Bangalore, India , Banja Luka, Bosnia and Herzegovina , Barnaul, Russia , Bhopal, India , Birobidzhan, Russia , Bucharest, Romania , Buenos Aires, Argentina and 110 more locations